BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25845427)

  • 1. Epithelial-to-mesenchymal transition in paired human primary and recurrent glioblastomas.
    Kubelt C; Hattermann K; Sebens S; Mehdorn HM; Held-Feindt J
    Int J Oncol; 2015; 46(6):2515-25. PubMed ID: 25845427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reciprocal regulation of the cholinic phenotype and epithelial-mesenchymal transition in glioblastoma cells.
    Koch K; Hartmann R; Schröter F; Suwala AK; Maciaczyk D; Krüger AC; Willbold D; Kahlert UD; Maciaczyk J
    Oncotarget; 2016 Nov; 7(45):73414-73431. PubMed ID: 27705917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversion of malignant phenotypes of human glioblastoma cells by β-elemene through β-catenin-mediated regulation of stemness-, differentiation- and epithelial-to-mesenchymal transition-related molecules.
    Zhu T; Li X; Luo L; Wang X; Li Z; Xie P; Gao X; Song Z; Su J; Liang G
    J Transl Med; 2015 Nov; 13():356. PubMed ID: 26563263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role Played by SLUG, an Epithelial-Mesenchymal Transition Factor, in Invasion and Therapeutic Resistance of Malignant Glioma.
    Oh SJ; Ahn EJ; Kim O; Kim D; Jung TY; Jung S; Lee JH; Kim KK; Kim H; Kim EH; Lee KH; Moon KS
    Cell Mol Neurobiol; 2019 Aug; 39(6):769-782. PubMed ID: 31011939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
    Wang H; Zhang H; Tang L; Chen H; Wu C; Zhao M; Yang Y; Chen X; Liu G
    Toxicology; 2013 Jan; 303():139-46. PubMed ID: 23146760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.
    Jeevan DS; Cooper JB; Braun A; Murali R; Jhanwar-Uniyal M
    Anticancer Res; 2016 Feb; 36(2):523-32. PubMed ID: 26851006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells.
    Drachsler M; Kleber S; Mateos A; Volk K; Mohr N; Chen S; Cirovic B; Tüttenberg J; Gieffers C; Sykora J; Wirtz CR; Mueller W; Synowitz M; Martin-Villalba A
    Cell Death Dis; 2016 Apr; 7(4):e2209. PubMed ID: 27124583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prosaposin is a biomarker of mesenchymal glioblastoma and regulates mesenchymal transition through the TGF-β1/Smad signaling pathway.
    Jiang Y; Zhou J; Hou D; Luo P; Gao H; Ma Y; Chen YS; Li L; Zou D; Zhang H; Zhang Y; Jing Z
    J Pathol; 2019 Sep; 249(1):26-38. PubMed ID: 30953361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line.
    Akiyama Y; Ashizawa T; Komiyama M; Miyata H; Oshita C; Omiya M; Iizuka A; Kume A; Sugino T; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Oncol Rep; 2014 Jul; 32(1):159-66. PubMed ID: 24842123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma.
    Iwadate Y; Matsutani T; Hirono S; Shinozaki N; Saeki N
    J Neurooncol; 2016 Aug; 129(1):101-7. PubMed ID: 27193555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Cumulative Analysis of Current Evidence for Association between Expression of Epithelial-Mesenchymal Transition Markers and Clinicopathological Outcomes in Patients after Radical Prostatectomy.
    Jiang G; Hu Q; Wang H; Ding W; Zhang N; Wu Y; Zhou Q; Sun C; Xia G; Ding Q; Na R; Xu K
    Ann Clin Lab Sci; 2018 Jan; 48(1):18-28. PubMed ID: 29530992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming growth factor-β pathway activity in glioblastoma.
    Frei K; Gramatzki D; Tritschler I; Schroeder JJ; Espinoza L; Rushing EJ; Weller M
    Oncotarget; 2015 Mar; 6(8):5963-77. PubMed ID: 25849941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line.
    Ashizawa T; Akiyama Y; Miyata H; Iizuka A; Komiyama M; Kume A; Omiya M; Sugino T; Asai A; Hayashi N; Mitsuya K; Nakasu Y; Yamaguchi K
    Int J Oncol; 2014 Jul; 45(1):411-8. PubMed ID: 24820265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.
    Wang YP; Yu GR; Lee MJ; Lee SY; Chu IS; Leem SH; Kim DG
    Hepatology; 2013 Oct; 58(4):1349-61. PubMed ID: 23696034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
    Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
    Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma.
    Chow KH; Park HJ; George J; Yamamoto K; Gallup AD; Graber JH; Chen Y; Jiang W; Steindler DA; Neilson EG; Kim BYS; Yun K
    Cancer Res; 2017 Oct; 77(19):5360-5373. PubMed ID: 28807938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.
    Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH
    OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.